Medtronic announces CE Mark for Stealth AXiS™ surgical system

Rhea-AI Summary

Medtronic (MDT) received CE mark for the Stealth AXiS™ surgical system on April 28, 2026, authorizing use across Europe for spine and cranial procedures. The platform integrates planning, navigation, and robotics with LiveAlign™ segmental tracking and AI-driven planning as part of the AiBLE™ ecosystem.

This follows U.S. FDA clearances earlier in 2026 and is positioned to expand access to integrated surgical workflows across diverse European healthcare systems.

Positive

• CE mark granted for Stealth AXiS on April 28, 2026
• Indicated for both spine and cranial procedures
• LiveAlign™ segmental tracking: industry-first real-time anatomical motion visualization
• Integrated planning, navigation, and robotics in one modular platform
• Part of AiBLE™ ecosystem with AI-driven planning and automatic tractography

Negative

• No commercial rollout timeline or regional launch dates disclosed
• No revenue guidance, pricing, or reimbursement information provided

News Market Reaction – MDT

-1.23%

-1.23% Session close to close

In the Apr 28 session, MDT declined 1.23%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement extends the Stealth AXiS™ platform into Europe via CE mark, building on earlier U....

Analysis

This announcement extends the Stealth AXiS™ platform into Europe via CE mark, building on earlier U.S. FDA clearances and integrating planning, navigation, robotics, and AI-enabled tractography into one system. It adds to a series of recent regulatory wins and acquisitions highlighted in prior news. Investors may track how quickly hospitals adopt this modular platform, how it contributes to Medtronic’s Neuroscience and spine franchises, and any follow-on updates in upcoming FY2026 results on June 3, 2026.

Historical Context

5 past events · Latest: Apr 20 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 20	CathWorks acquisition	Positive	-1.4%	Completion of $585M CathWorks deal adding AI-driven FFRangio system.
Apr 13	Earnings date set	Neutral	+0.9%	Announcement of Q4 and full-year FY26 results date and webcast details.
Mar 27	Stealth AXiS FDA OK	Positive	-0.6%	FDA clearance for Stealth AXiS system for cranial and ENT procedures.
Mar 23	OmniaSecure approval	Positive	+1.2%	FDA approval expanding OmniaSecure defibrillation lead indication for CSP.
Mar 10	Scientia deal	Positive	-1.6%	Agreement to acquire Scientia Vascular for $550M to expand neurovascular tools.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent positive regulatory and acquisition news often saw mixed to negative next-day reactions, with several divergences where approvals or strategic deals coincided with share price declines.

Recent Company History

Over the past months, Medtronic has focused on portfolio expansion and regulatory milestones. It agreed to acquire Scientia Vascular and completed the $585 million CathWorks acquisition, both followed by modest share price declines. Multiple FDA clearances, including the Stealth AXiS™ system and OmniaSecure™ lead, highlighted innovation momentum, with reactions ranging from -0.6% to +1.17%. An upcoming FY2026 earnings date on June 3, 2026 sets the stage for financial updates alongside this new European CE mark.

Key Terms

ce mark, eu medical device regulation (mdr), tractography

3 terms

ce mark regulatory

"has received CE mark for the Stealth AXiS™ surgical system"

A CE mark is a regulatory stamp placed on products to show they meet the European Union’s basic safety, health and environmental rules and can be sold in the European Economic Area. For investors it matters because the mark unlocks market access, affects how quickly a product can generate revenue, and signals regulatory risk and potential compliance costs—think of it as a passport that lets a product enter a large market.

eu medical device regulation (mdr) regulatory

"under EU Medical Device Regulation (MDR), underscores our commitment"

A set of European Union rules that sets safety, testing and approval requirements for medical devices sold in Europe, from bandages to implantable equipment. Think of it as a strict building code and inspection system for health products: manufacturers must prove safety and effectiveness, maintain ongoing monitoring, and get an EU safety mark before selling. Investors care because compliance affects a device maker’s ability to sell in Europe, costs, timelines, liability and competitive position.

tractography medical

"features AI-powered automatic tractography, allowing surgeons to create"

Tractography is an imaging method that uses MRI data to map the brain’s internal wiring by tracking the paths of water movement along nerve fiber bundles. For investors, it matters because it underpins advanced diagnostics, surgical planning, and the development of medical devices or software that analyze brain connectivity — similar to a GPS map for a city’s highways, helping doctors and companies locate and navigate critical routes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Following recent FDA clearances, Medtronic is accelerating access to integrated planning, navigation, and robotics platform across Europe

GALWAY, Ireland, April 28, 2026 /PRNewswire/ -- Medtronic, a global leader in healthcare technology, has received CE mark for the Stealth AXiS™ surgical system, a next-generation platform that brings planning, navigation, and robotics together into one single, intelligent system. The Stealth AXiS™ system is indicated for spine and cranial procedures, highlighting the platform's scalability across multiple surgical specialties for Medtronic.

"Receiving CE mark for the Stealth AXiS™ system marks an important milestone in expanding access to advanced surgical technologies across Europe," said Oli Prosperi, Vice President, International Commercial, Cranial & Spinal Technologies, Medtronic. "Achieving CE mark in the current regulatory environment, under EU Medical Device Regulation (MDR), underscores our commitment to bringing meaningful innovation into a highly diverse healthcare landscape." 

The Stealth AXiS™ system represents major advancement in surgical technology by integrating planning, navigation, and robotic execution into a single, modular platform. Designed to support a wide range of clinical workflows and surgical environments, the system enables hospitals to adopt capabilities based on their needs, while maintaining flexibility for future expansion.

A key innovation of the system is LiveAlign™ segmental tracking, an industry-first capability that allows surgeons to visualize anatomical motion and patient alignment in real time during spine procedures. As a cornerstone of Medtronic's AiBLE™ ecosystem, the Stealth AXiS™ system connects pre-, intra-, and post-operative workflows, enabling a more integrated approach to surgical care.

A key strength of the platform lies in its AI-driven architecture, which enables advanced planning and visualization across all stages of surgery - before, during, and after the procedure. In cranial applications, it features AI-powered automatic tractography, allowing surgeons to create patient-specific brain maps and clearly visualize critical neural pathways linked to essential brain functions.

"The introduction of the Stealth AXiS™ system to Europe reflects our focus on delivering connected platforms that improve precision, efficiency, and consistency across diverse healthcare systems," said Michael Carter, Senior Vice President and President of Cranial & Spinal Technologies at Medtronic. "By bringing planning, navigation, and robotic guidance into a unified workflow, we are helping surgeons translate insight into action in the operating room, supporting more predictable and personalized care while building a strong foundation for continued innovation."

The CE mark follows U.S. FDA clearances earlier this year, highlighting Medtronic's ability to rapidly bring advanced surgical technologies to global markets.

For more information about the Stealth AXiS™ surgical system and the AiBLE™ smart ecosystem, visit our website.

About the Cranial & Spinal Technologies Business at Medtronic
As the global market leader, Medtronic Cranial and Spinal Technologies is transforming the standard of care in spine and cranial surgery by putting patients first and addressing the complex challenges faced by spine and neurosurgeons. With a portfolio of 150 products covering more than 20 pathologies, we serve over 4 million patients annually. Building on a legacy of innovation, our AiBLE™ ecosystem integrates advanced technologies, data, and AI with a patient-centric approach, offering customizable solutions to enhance surgical precision, improve workflow efficiency, and achieve better outcomes, before, during, and beyond surgery.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:
Maria Trenzado
Communications for Western Europe
maria.trenzado@medtronic.com

Ingrid Goldberg
Investor Relations
+1-763-505-2696

View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-announces-ce-mark-for-stealth-axis-surgical-system-302754990.html

SOURCE Medtronic plc

FAQ

What does Medtronic's CE mark for Stealth AXiS (MDT) mean for European use?

The CE mark permits European marketing and use of Stealth AXiS for spine and cranial procedures. According to the company, the clearance enables hospitals across Europe to adopt the integrated planning, navigation, and robotics platform under EU MDR regulatory authorization.

Which surgical indications are cleared for Stealth AXiS (MDT) in Europe?

Stealth AXiS is indicated for both spine and cranial surgical procedures. According to the company, the platform is designed to support multiple specialties and scalable clinical workflows across those indications.

What is LiveAlign™ segmental tracking on Stealth AXiS (MDT)?

LiveAlign is an industry-first feature that visualizes anatomical motion and patient alignment in real time during spine surgery. According to the company, it enables surgeons to monitor segmental motion intraoperatively for enhanced alignment decisions.

How does Stealth AXiS (MDT) use AI in cranial procedures?

The system features AI-powered automatic tractography to create patient-specific brain maps. According to the company, this helps visualize critical neural pathways and supports surgical planning and intraoperative navigation.

Does the CE mark for Stealth AXiS (MDT) follow any prior approvals?

Yes, the CE mark follows U.S. FDA clearances granted earlier in 2026. According to the company, these regulatory milestones support broader global availability of the integrated Stealth AXiS platform.